S1 Clinical diabetes and therapeutics 1 :
Lessons from large clinical trials in diabetes mellitus
Friday 29 September 09:00~11:00 | Place: Convention hall A
Chairman: Doo Man Kim, Ho Sang Shon
    • Lessons from large clinical trials in diabetes mellitus Diabetic vascular complications are main causes of mortality and morbidity in patients with diabetes mellitus. Recently large prospective clinical trials have assessed the benefits and risks of new anti-diabetes and anti-lipid agents. In this session, four outstanding researchers will cover the lessons from the large clinical trials in terms of microvascular complications, macrovascular complications of T2DM, T1DM, and lipid management. Professor Kang will review the microvascular outcomes of T2DM from UKPDS to CANVAS-R study. Professor Kim will talk about the update on cardiovascular outcomes trials of T2DM. Professor Kim, pediatric endocrinologist, will present about the glucose control and vascular outcomes of T1DM. And Professor Choi will give a lecture about insights from new emerging lipid lowering therapy in dyslipidemia patients with diabetes: PCSK9 inhibitors, CETP inhibitors, and MTTP inhibitors. This session will give an informative and interesting inspiration in the clinical therapeutic field of diabetes mellitus.
Eun Seok Kang Yonsei University, Korea S1-1 Review of microvascular outcomes trials of type 2 diabetes - From UKPDS to CANVAS-R
Sin Gon Kim Korea University, Korea S1-2 Update on cardiovascular outcomes trials of type 2 diabetes - From RECORD to DEVOTE
Jae Hyun Kim Seoul National University, Korea S1-3 Summary of glucose control and vascular outcomes of type 1 diabetes - From DCCT to REMOVAL
Sung Hee Choi Seoul National University, Korea S1-4 Insights from new emerging lipid lowering therapy in dyslipidemia patients with diabetes-PCSK9 inhibitors, CETP inhibitors, MTTP inhibitors
S6 Clinical diabetes and therapeutics 2 :
Insulin therapy in type 2 diabetes mellitus
Friday 29 September 16:00~18:00 | Place: Convention hall A
Chairman: Moon-Gi Choi, Jeong Taek Woo
    • Insulin therapy in type 2 diabetes mellitus Insulin therapy could be an option or should be initiated in patients with type 2 diabetes (T2D), as their capacity to secrete their own insulin from pancreatic β-cells declines progressively. The questions remain as to when insulin therapy should be started, and which type of insulins is the most appropriate for T2D on basis of individualized approach. The first speaker, Prof. Soon-Jip Yoo, will present about the dilemmas of insulin-based therapies in clinical practice especially based on their effectiveness and safety. The next speaker, Prof Yehuda Hadelsman, will clearly overview the insulin therapy guideline in T2D to guide the physicians to the appropriate use of insulin in real clinical practice. Dr. Paul Norwood gives a novel insight on the option for controlling the postprandial glucose which is the main problem to achieve target HbA1c. The last speaker, Prof. Young Min Cho, address both his clinical experience and scientific knowledge that he knew from his recent meta-analysis. This scenario of insulin usage might be interest to you.
Soon Jib Yoo The Catholic University of Korea, Korea S6-1 Dilemmas of insulin-based therapy in clinical practice: effectiveness vs safety
Yehuda Handelsman Metabolic Institute of America, USA S6-2 The contemporary approach to insulin therapy
Paul Norwood University of California at San Francisco, USA S6-3 Insulin, past, present and future
Young Min Cho Seoul National University, Korea S6-4 Add-on drugs to insulin therapy: comparative effectiveness
S11 Clinical diabetes and therapeutics 3 :
Making an impact on diabetes in pregnancy
Saturday 30 September 09:00~11:00 | Place: Convention hall A
Chairman: Nam Han Cho, Seok Won Park
    • Making on impact on diabetes in preganacy Hyperglycemia is one of the most common medical conditions women encounter during pregnancy. It is important to have awareness of the links between hyperglycemia and maternal and fetal outcomes as well as to the future health risks to mother and offspring. For making an impact on managing diabetes in pregnancy, we will discuss about the updated guidance for testing and management, and new outcomes data of women with DM in pregnancy. The first speaker, Prof Yang Huixia will present about the update of testing for GDM diagnosis and monitoring. The next speaker, Kyung-Soo Kim discuss about the effect of oral anti diabetic agents on maternal and fetal outcomes to provide an evidence-based approach. The next part of this session will be presented about the maternal and fetal outcomes in Korean women with diabetes in pregnancy by prof. Sung-Hoon Kim and the association of hyperglycemia and adverse pregnancy outcomes in recent clinical trial results by prof. Eun-Hee Cho.
Huixia Yang Photosynthesis Research Center, China S11-1 A universal consensus on GDM diagnosis & monitoring
Kyung-Soo Kim CHA University, Korea S11-2 Effect of oral anti-diabetic agents on maternal and fetal outcomes: do we have enough evidences to use in pregnancy?
Sung-Hoon Kim Dankook University, Korea S11-3 Pregnancy outcomes in Korean women with diabetes
Eun-Hee Cho Kangwon National University, Korea S11-4 Hyperglycemia and adverse pregnancy outcome: HAPO FUS
S14 Clinical diabetes and therapeutics 4 :
New IT-based management of diabetes
Saturday 30 September 14:30~16:30 | Place: Convention hall A
Chairman: Kun-Ho Yoon, Jeong Hyun Park
    • Information technology (IT) has been rapidly developing, and smartphone is a very popular device nowadays, which enable to ubiquitous healthcare (U-healthcare) in many chronic diseases. Obesity and diabetes might be most suitable target diseases for IT- or U-healthcare based medicine, as they are very prevalent and have chronicity. The first part of this session will be presented by professor Eun Ky Kim (Seoul National University, Korea) and professor Sang Youl Rhee (Kyung Hee University, Korea) about updated information of smarphone-based management for diabetes and obesity, respectively. The second part of the session will be about the artificial pancreas (AP), a system combining a glucose sensor, a control algorithm, and an insulin infusion device. Dr. Stefania Guerra (Dexcom) will provide the updated information on Continuous Glucose Monitoring). Dr. John Shin (Director at Medtronic Diabetes, USA) will introduce the clinical data on 670G, the first FDA-approved AP.
Eun Ky Kim Seoul National University, Korea S14-1 Smartphone-based diabetes care system for patients with type 2 diabetes
Sang Youl Rhee Kyung Hee University, Korea S14-2 Obesity management using smartphone applications: is it really effective?
Stefania Guerra Dexcom, Inc, USA S14-3 Continuous glucose monitoring: the past, the present, the future
John J. Shin Medtronic Diabetes, USA S14-4 The artificial pancreas in the real world
Quick Menu
Registration
Abstract
On-line submission
Venue
venue
Top